<DOC>
	<DOCNO>NCT01423760</DOCNO>
	<brief_summary>This open-label , common follow-up trial . Subjects enrol Merck KGaA , EMD Serono Merck Serono Japan sponsor trial tecemotide ( L-BLP25 ) enrol follow-up trial continue maintenance treatment tecemotide ( L-BLP25 ) . Subjects transfer feeder trial ( EMR 63325-005 [ NCT00157209 ] , EMR 63325-006 [ NCT00157196 ] EMR 63325-008 [ NCT01094548 ] ) objectives meet . Subjects receive tecemotide ( L-BLP25 ) feeder trial continue tecemotide ( L-BLP25 ) treatment follow-up trial safety assessment perform well observed progressive disease ( PD ) survival 6- month interval . Subjects receive tecemotide ( L-BLP25 ) feeder trial , discontinue treatment observed PD survival 6-month interval provide treatment tecemotide ( L-BLP25 ) .</brief_summary>
	<brief_title>Common Safety Follow-up Trial Tecemotide ( L-BLP25 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Signed write informed consent . Registration treatment clinical trial tecemotide ( LBLP25 ) sponsorship Merck KGaA/EMD Serono/Merck Serono Japan ( feeder trial ) . [ Note , subject allocate treatment contain tecemotide ( L BLP25 ) feeder trial eligible trial followedup progressive disease ( PD ) ( applicable ) survival . ] End Treatment procedure perform feeder trial . Other protocol define inclusion criterion could apply Exclusion Criteria Pregnancy lactation period ; woman childbearing potential , unless use effective contraception determine Investigator . Subjects Investigator considers may risk pregnancy pregnancy test perform per institutional standard Known hypersensitivity trial treatment ingredient ( applicable ) Legal incapacity limit legal capacity Any reason , opinion Investigator , preclude subject participate trial Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Stimuvax</keyword>
	<keyword>Tecemotide</keyword>
	<keyword>L-BLP25</keyword>
	<keyword>Non-Small Cell Lung Carcinoma</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>